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Endothelial cells (EC) form a semi-permeable barrier between the interior space of blood 
vessels and the underlying tissues. In acute lung injury (ALI) the EC barrier is weakened 
leading to increased vascular permeability. It is widely accepted that EC barrier integrity is 
critically dependent upon intact cytoskeletal structure and cell junctions. Edemagenic 
agonists, like thrombin or endotoxin lipopolysaccharide (LPS), induced cytoskeletal 






















































EC permeability increase. The highly clinically-relevant cytoskeletal mechanisms of EC 
barrier dysfunction are currently under intense investigation and will be described and 
discussed in the current review. 
Introduction. Lung endothelium forms a semi-permeable barrier between the blood and 
the interstitial space.
1
 Disruption of endothelial barrier results in the movement of fluid and 
macromolecules into the interstitium and pulmonary air spaces causing pulmonary edema 
which is a common feature of Acute Lung Injury (ALI) and its more severe form Acute 
Respiratory Distress Syndrome (ARDS). The integrity of pulmonary EC monolayer is a 
critical requirement for tissue and organ homeostasis. EC barrier is heavily dependent upon 
the EC cytoskeleton network primarily microfilaments and microtubules which tightly linked 
to cell junction proteins.
1-4
 This review will describe the cytoskeletal mechanisms of EC 
permeability increase, induced by various inflammatory conditions focusing on edemagenic 
agonists, like LPS and thrombin.  
Clinical and physiological importance of the lung vascular barrier. The alveolar-
capillary barrier is formed by the microvascular endothelium, the alveolar epithelium and the 
basement membrane. Direct or indirect injuries of the lung caused by inflammatory or toxic 
mediators can lead to pathophysiological syndromes such as severe pneumonia and 
ALI/ARDS. Despite recent therapeutic advances, these conditions still have high (30-40%) 
rates of patient mortality.
5
 The acute phase of lung injury is characterized by a massive and 
rapid flood of protein rich edema fluid into the alveolar spaces as a consequence of increased 
endothelial permeability
5
 (Fig. 1). Neutrophils are adhering to the injured endothelium and 
migrating through the interstitium into the alveoli,
6, 7
 whereas the macrophages are secreting 
cytokines (IL-1, 6, 8 and 10) and TNFα.8 ALI/ARDS leads to impaired gas exchange and may 
cause respiratory failure.
9
 It is widely accepted that EC barrier dysfunction, a prominent 






















































remodeling resulting in the disruption of cell-cell contacts, paracellular gap formation and EC 
barrier compromise.
3, 4
 Apart from ventilation strategies there is no standard treatment for 
pulmonary edema, making the investigation of regulatory mechanisms of endothelial barrier 
dysfunction highly clinically important.
5
  
Endothelial barrier properties. The vascular endothelium serves as a semi-selective 
barrier lining in the vessel walls (Fig. 1). It dynamically regulates the liquid and 
macromolecule transport between the blood and the interstitial space.
10
 The vasculature is 
lined by heterogeneous population of endothelial cells. This heterogeneity is derived from the 
origin of endothelial cells in the vascular tree. The barrier function, surface biochemistry, and 
morphology of confluent monolayers of microvascular and macrovascular endothelial cells 
are different for these two cell types.
11
  In general, microvascular EC form a tighter barrier, 
compared to macrovascular one. It was found that permeability is ~16-fold less for sucrose 
and to 2-fold less for albumin in microvascular EC compared to macrovascular EC 
monolayers. 
12
 Conversely, primary cultures of microvascular EC produced 10 times higher 
transmonolayer electrical resistance (TER) compared to macrovascular one.
13
 Although the 
precise mechanisms that regulate this variability are still under investigation, microarray 
analysis showed a significant variation in microvascular and macrovascular gene expression 
patterns.
14
 Extracellular matrix proteins, collagen 4α1, collagen 4α2, and laminin were 
associated with microvessel endothelia, while fibronectin, collagen 5α1, and collagen 5α2 
were seen with the large vessel endothelia.
14
 Furthermore, electron microscopy revealed that 
microvascular EC have more developed intercellular junctions with more focal membrane 
adhesion sites per junction than the macrovascular cells.
12
 Pulmonary artery endothelial cells 
(macrovascular EC) participate in blood homeostasis, blood-tissue exchange regulation under 
various conditions.
15
 They share similarities in cell characteristics and in physiological 






















































suggest that most fluid filtration occurs in the microcirculation.
16
   
Endothelial permeability pathways. A variety of physical, inflammatory and bioactive 
stimuli alter the EC barrier leading to gap formation, increasing vessel permeability and 
compromising organ function. Permeability across endothelial and epithelial cell monolayers 
can involve transcellular, paracellular or the combination of both pathways (Fig. 2). The 
transcellular transport involves membrane-attached cytosolic caveolae that migrate through 
the endothelial cells and transfer macromolecules from the blood to the interstitium.
10
 The 
main player in this process is the Src kinase, which can phosphorylate caveolin-1 on tyrosine 
residues inducing the migration of the vesicles across the endothelium.
17
 Recent studies 
demonstrated that transcellular permeability increase precedes and may trigger paracellular 
permeability increase via signaling involved Src-mediated phosphorylation of caveolin-1.
18
 
However, majority of trafficking occurs through the paracellular route,
19
 which will be 
described in this review in more details.  
External stimuli leading to EC barrier compromise. The capillary endothelium is 
impermeable to macromolecules under basal conditions. This is due to the network of 
cytoskeletal and cell-junction elements which protect the endothelial barrier integrity. In state 
of acute or chronic inflammation, sepsis, diabetes, angiogenesis, or excessive level of 
mechanical alterations (stretch or shear stress), the EC barrier integrity is compromised. 
Inflammatory mediators such as LPS, thrombin, pro-inflammatory cytokines, or reactive 
oxygen species induce the loss of endothelial barrier function leading to permeability increase 
to solute and plasma proteins.
20-23
 
LPS, a pro-inflammatory mediator and constituent of Gram-negative bacterial cell wall, 
directly disrupts macro- and microvascular EC barrier function in vitro and in vivo.
20, 24, 25
 
LPS primarily acts through the activation of toll-like receptor 4 (TLR4).
26
 LPS-induced EC 






















































cytoskeletal proteins that participate in cell-cell and cell-matrix adhesion.
25
 Signal 
transduction mechanisms for LPS-induced EC permeability are not completely clear yet, but 
likely involve Tyr kinase(s), protein kinase C (PKC) as well as Rho signaling.
27-30
 Murine 
lung injury induced by LPS is a model that has been shown to be largely consistent with 
sepsis-induced ALI.
31
 Specifically, the injury elicited is characterized by neutrophil 
infiltration into the lung in association with increased inflammatory mediators including 
TNFα and NF-kB.31  
Thrombin is a serine protease generated by injured endothelial cells by the cleavage of 
circulating prothrombin, participating in the prothrombinase complex which also contains 
factors X and V, Ca
2+
 and membrane phospholipids.
32
 Thrombin not only induces 
coagulation, but also affects endothelial barrier function by releasing of inflammatory 
mediators and growth factors  as well as inducing leukocyte adhesion on EC surface.
33
 The 
cellular responses of EC to thrombin are mainly mediated through a thrombin-specific 




 In vitro, thrombin produces rapid, reversible, 
concentration-dependent increases in EC permeability as measured by the clearance rate of 
Evans blue dye-labeled albumin across EC monolayers
37, 38
 or by changes in transendothelial 
electrical resistance.
21, 39, 40
 Thrombin infusion in animals resembles that seen after LPS 
administration in several respects, including pulmonary hypertension and increased 
pulmonary vascular permeability.
41, 42
 Interestingly, thrombin inhibitor, anti-thrombin III (AT 
III) prevents LPS-induced pulmonary vascular injury suggesting the involvement of thrombin 
in LPS-induced permeability response.
43
 
Contractile mechanisms of EC permeability. Endothelial barrier integrity is maintained 
by the precisely regulated balance between  actomyosin contractile forces and adhesive cell-
cell, cell-matrix tethering forces.
4
 Both competing forces are generated by the cytoskeleton 
comprising actin microfilaments, microtubules and intermediate filaments.
3, 4






















































complex network of cytoskeleton is critical in the EC barrier regulation. Disruption of either 
intact actin or microtubule network leads to formation of paracellular gaps and permeability 
increase.
44, 45
 Under quiescent conditions, when the balance is tilted towards tethering forces, 
a thick cortical actin ring can be observed, where endothelial cells can maintain tight 
connections with each other and the underlying matrix.
3, 4
 Due to the effect of barrier-
compromising agents like thrombin or LPS, the balance is shifted towards contractile forces 
(Fig. 3).  
Thrombin cleaves and activates its G-protein-coupled receptor (PAR-1). Engagement of 







 elevation activates the Ca
2+
/calmodulin (CaM) dependent myosin light chain (MLC) 
kinase (MLCK) that phosphorylates MLC and, consequently, actomyosin interaction and cell 
contraction will be evoked.
47, 48
 Beside the Ca
2+
/CaM-induced activation, endothelial (non-
muscle) MLCK can be activated by Src-mediated Tyr phosphorylation on its unique N-
terminal fragment, which is absent in smooth muscle (SM) MLCK.
49
 Thrombin was shown to 




Additionally, thrombin and LPS induced MLC-mediated EC contractile response and 
permeability via activation of Rho signaling pathway.
21, 29
 The Ras homologous small GTPase 
Rho acts as molecular switch, cycling between an active GTP-bound and inactive GDP-bound 
state.
51
 Rho activity is positively regulated by guanosine nucleotide exchange factors (GEFs) 
and inhibited by GTPase-activating proteins (GAPs), and GDP-dissociation inhibitors 
(GDIs).
52
 Thrombin induced Rho activation involved G12/13-mediated activation of 
p115RhoGEF, GEF-H1 activation, as well as PKC-mediated inhibition of GDI-1.
21, 53, 54
 LPS-
induced Rho activation dependent upon the activity of Src family kinases and direct nitration 


























































kinase, which increases MLC phosphorylation by two mechanisms: directly, via 
phosphorylation of MLC at Ser
19
 and indirectly, via phosphorylation of the targeting subunit 





 sites leads to the inhibition of MLCP, accumulation of phospho-MLC 





Inhibition of MLCP also can be achieved through activation of CPI-17 (PKC potentiated 
inhibitory protein of 17 kDa). This soluble globular protein was first identified in SM cells, 
and later was found in several non-muscle cells including microvascular EC.
58, 59
 
Phosphorylation of CPI-17 at Thr
38
 by PKC increases its inhibitory potency toward MLCP 
~1000-fold.
60,61
 Histamine and thrombin (to a lesser extent) activate CPI-17 in PKC-
dependent manner in ECs.
58
 CPI-17 depletion significantly attenuates histamine-induced 
microvascular permeability increase implicating CPI-17-mediated mechanism of MLCP 
inhibition in EC barrier regulation
58
 (Fig. 3).   
EC barrier dysfunction and cytoskeletal rearrangement are not always associated with 
triggering contraction by an increase in MLC phosphorylation. Some agonists, like direct 







 Phorbol ester-induced EC barrier dysfunction is accompanied by increased 
phosphorylation of a cytoskeletal protein, caldesmon (CaD).
63-65
 CaD contains distinct 
binding sites for actin and myosin, thereby potentially regulating actomyosin interactions and 
promoting actin filament formation in the absence of MLC phosphorylation.
66-68
 Phorbol 
ester-induced phosphorylation of CaD correlates with contraction and has been postulated as 
an on/off switch regulating actomyosin interactions in smooth muscle.
67
 It is clear that CaD is 
directly involved in EC cytoskeletal arrangement and migration,
69
 however, the functional 
significance of CaD phosphorylation in the regulation of EC barrier function have not been 






















































Interestingly, PKC does not directly phosphorylate CaD. Phorbol ester-induced EC 
barrier dysfunction includes complex signaling involving sequential activation of Ras, Raf-1 
and MEK resulting in activation of ERK1/2 MAP kinases,
70
 which phosphorylate CaD and 
are responsible for CaD-mediated contractile response in smooth muscle.
67
 Aside of ERK 1/2, 
another MAPK family member, p38 kinase is also directly involved in EC cytoskeletal 
remodeling and permeability.
71-73
 p38, but not ERKs, is involved in thrombin-induced EC 
barrier compromise
73
 and p38 signaling is involved in several in vivo models of lung injury 
including the LPS model of ALI.
74-76
 p38 MAPK downstream targets contain several 
cytoskeletal proteins such as CaD and HSP-27.
77, 78
  
Small heat shock actin-capping protein, HSP-27, is phosphorylated by MAP kinase-
activated protein kinase 2 (MAPKAP kinase 2), that is in turn phosphorylated by p38 
MAPK.
77, 79
 Phosphorylation of HSP-27 promotes F-actin formation, membrane blebbing and 




 However, the 
role of HSP-27 in the regulation of EC permeability remains controversial. For example, 
pertussis toxin-induced EC permeability is temporally linked to p38 MAPK activation and 
phosphorylation of HSP-27 in EC
72; and LPS-induced endothelial barrier dysfunction 
correlates with HSP-27 phosphorylation in vivo.
76
 In contrary, depletion of HSP-27 did not 
prevent p38-mediated TGFβ-induced EC barrier dysfunction.83  Therefore, the exact 
cytoskeletal targets of p38 MAPK in endothelium remain undetermined. The putative targets 
include ezrin/radixin/moesin (ERM) proteins, which may be phosphorylated through p38-
dependent mechanisms,
84
 but apparently, the role of ERM phosphorylation in EC barrier 
regulation is agonist-specific.
84-87
 A few studies implicated the involvement of p38 activity in 
the activation of Rho/Rho kinase pathway and EC barrier dysfunction induced by TGFβ and 
Staphylococcus aureus-derived toxins.
83, 88
 In contrast, inhibition of p38 has no effect on 
thrombin-induced MLC phosphorylation, which involves Rho activation.
21, 73


























































Crosstalk between microtubules and microfilaments in EC permeability regulation. 
Paracellular gap formation evoked by barrier-disruptive agents resulting in increased 
endothelial permeability is governed by the coordinated communication among cytoskeletal 
elements. Disruption of microtubule (MT) structure leads to an increase in transendothelial 
permeability associated with a characteristic loss of the peripheral actin band as well as an 
increase in the density of actin stress fibers, increased levels of MLC phosphorylation, 
consistent with actomyosin contraction, and paracellular gap formation.
45, 89
 Further, 
microtubule dissolution increased vascular permeability in murine model.
75
 Vice versa, 
stabilization of microtubules protects EC monolayer in vitro and in vivo.
75, 90, 91
 Edemagenic 
agonists like thrombin, LPS, TNFα and TGFβ induce partial microtubule dissolution 
accompanied by activation of EC contraction and permeability increase.
91-94
 The effect of 
microtubule dissolution on actin reorganization is attributed to stimulation of Rho and p38 
MAPK pathways, but not to an increase in [Ca
2+




In the thrombin model of EC permeability microtubule disassembly precedes actin stress 
fiber formation.
96
 Thrombin may induce microtubule dissolution via stimulation of 
G12/13/p115RhoGEF cascade, followed by Rho/Rho kinase activation, resulting in 
phosphorylation of the microtubule-associated protein, tau.
93
 In its unphosphorylated form, 
tau promotes assembly of microtubules and inhibits the rate of depolymerization.
97-99
 
Phosphorylation of tau decreases its capacity to bind microtubules and promotes MT 
assembly. 
99, 100
 Interestingly, p38 MAPK is also able to phosphorylate tau in vitro.
101
 
Inhibition of p38 attenuates microtubule dissolution and permeability increase induced by 
various agonists
94, 102






















































in MT destabilization via tau phosphorylation.  
Thrombin may also destabilize microtubules via Rho kinase-mediated phosphorylation 
and activation of LIM kinase (LIMK).
103
 In quiescent conditions, LIM kinase is associated 
with microtubules. Thrombin treatment or ectopic expression of Rho kinase leads to 
dissociation of LIM kinase from microtubules accompanied by MT destabilization, 
phosphorylation/inhibition of cofilin, an actin depolymerization factor, resulting in F-actin 
assembly.
103
   
It was also recently reported that thrombin may destabilize microtubules via 
dephosphorylation of stathmin, a MT-associated protein, which in its phosphorylated form 
stabilizes the microtubules.
104
 However, the thrombin-induced phosphatase, which is able to 
dephosphorylate stathmin and is involved in thrombin-induced permeability increase, is not 
known yet.  
Thrombin-induced microtubule dissolution may further activate Rho pathway via GEF-
H1, which has been recently characterized as a Rho-specific GEF localizing on microtubules. 
105
 In its MT-bound state, GEF-H1 is inactive, whereas GEF-H1 release caused by MT 
disassembly stimulates its activity towards Rho.
106
 Importantly, GEF-H1 is directly involved 
in thrombin-induced permeability increase.
53
 
Microtubule dissolution may also affect cellular localization and activity of cytoskeletal 
regulatory proteins like CaD, which can be involved in EC barrier regulation. CaD co-purifies 
with microtubules from brain and potentiates tubulin polymerization.
107, 108
 Phosphorylation 
of CaD by cell cycle-dependent cdc2 kinase (Pro-directed kinase, similar to MAPK) 
eliminates MT-binding activity of CaD, and also decreases CaD-mediated inhibition of 
actomyosin ATPase, consistent with contraction.
107, 108
 Ectopic expression of CaD in 
fibroblasts eliminates the increase in focal adhesions and microfilament bundles induced by 
























































Current findings describing the role of microtubule/microfilament crosstalk in thrombin 
permeability model are summarized on Fig. 4. Thrombin may induce cytoskeletal 
reorganization leading to permeability increase in two phases. In the initial phase thrombin-
induced engagement of heterotrimeric G-proteins activates Rho (via p115RhoGEF) and p38 
MAPK pools associated with microtubules, resulting in phosphorylation/activation of MT-
associated proteins, like LIMK, tau and CaD. In addition, thrombin destabilizes microtubules 
by dephosphorylation of stathmin. In the final stage MT dissolution releases MT-associated 
protein complexes, further activating Rho (via GEF-H1) and p38 MAPK pathways, leading to 
increased phosphorylation of cytoskeletal targets, stress fiber formation, and barrier 
compromise.  
Endothelial cell junctions and barrier regulation. The vascular endothelium is 
constantly exposed to hemodynamic stimuli, such as shear stress, contraction or dilation of the 
vessels. The continuous reorganization of cell junctions and the cytoskeleton have key 
importance in the maintenance of the endothelial barrier integrity. Reshaping of the cells 
allows the endothelial monolayer to adapt to the dynamic conditions to which it is exposed.
110
 
Inter-endothelial communicating structures mainly comprise of adherens junctions (AJ), tight 
junctions (TJ) and gap junctions (GJ) (Fig. 5).  
AJs are critical in the maintenance of endothelial integrity providing connection between 
neighboring ECs, thus regulating endothelial barrier function. AJs represent the majority of 
cell junctions comprising the endothelial barrier, in contrast with epithelial cells where tight 
junctions dominate.
10
 AJs are composed of VE-cadherin and its cytoplasmic binding partners: 
α-, β- γ-, p120 catenins, which link AJs to the actin cytoskeleton. The assembly of the VE-






























































 The extracellular region contains five repeating domains 
which coordinate with calcium ions and form a rod-like structure. The intracellular tail of VE-
cadherin has two domains, the juxtamembrane domain (JMD) and the C-terminal domain 
(CTD). JMD binds p120 catenin, while CTD binds -catenin or plakoglobin (γ-catenin) which 
attach α-catenin to link the cadherin-catenin complex to the actin cytoskeleton. α-catenin also 
interacts with other actin-binding proteins, specifically, α-actinin, vinculin, TJ zonula 
occludin proteins: ZO-1, ZO-2, ZO-3 and possibly spectrin. VE-cadherin is critical for the 
proper assembly of AJs, and for normal endothelial barrier function.
112
 VE-cadherin impairing 
results in interstitial edema and inflammation in lung and heart microvasculature.
113
 
Catenins also play an important role in the regulation of AJ assembly. -catenin has a 
dual role in cells. First it was identified as a component of AJs in the late ‘80s. Kemler and 
colleagues were able to isolate -catenin together with α-catenin and plakoglobin.114 Later 
genetic and embryogenic studies revealed -catenin as a component of the Wnt signaling 
pathway playing an important role in embryonic development and tumorogenesis.
115
 Recent 
study implicates the involvement of Wnt signaling in EC barrier regulation.
116
 
Plakoglobin plays an important role in cadherin/catenin complex assembly, as a linker 
between this complex and F-actin cytoskeleton.
117
 Plakoglobin is an intracellular binding 
partner for VE-cadherin in ECs and its main function is to stabilize the AJ complex.
117, 118
 
Through α-catenin, plakoglobin is in connection with actin-binding proteins, like α-actinin 
and ZO-1.
119
 Plakoglobin is closely related to β-catenin, sharing 80% sequence identity120 and 
can bind the cytoplasmic domains of the classical cadherins. Both -catenin and plakoglobin 
were shown to stabilize the linkage between VE-cadherin and the actin cytoskeleton, thus 
regulating endothelial barrier function.
10
 Thrombin-induced release of β-catenin and p120 
catenin from the cell membrane has been described recently in human endothelium.
121
 

























































Regulation of AJs assembly and junctional permeability by reversible 
phosphorylation.  The dynamic assembly and disassembly of AJs depends on protein-protein 
interactions regulated by reversible phosphorylation. Histamine, tumor necrosis factor (TNF) 
and vascular endothelial growth factor induced tyrosine phosphorylation of VE-cadherin, -
catenin and p120 thus increasing endothelial barrier permeability.
123
 For instance, tyrosine 
phosphorylation on Tyr
860
 of VE-cadherin and Tyr
654
 on -catenin leads to disassembly of the 
catenin-cadherin complex.
124
 G12 binding to VE cadherin stimulates Src-mediated VE-
cadherin phosphorylation at Tyr
658
 leading to AJ disassembly.
125
 Recent studies revealed the 
possibility of AJ regulation by Ser/Thr phosphorylation as well. For example, activation of 
PKCα leads to phosphorylation of p120 catenin at Ser879 resulting in AJs disassembly.126 The 
cytoplasmic domain of VE-cadherin is phosphorylated at Ser
684,-686,-692
 creating more 





) which are phosphorylated by casein kinase 2 (CK-2) and glycogen 
synthase kinase 3 (GSK-3). This phosphorylation of cadherin could stabilize and strengthen 
the catenin-cadherin complex by several hundred folds.
111, 127, 128
 However, there are some 
reports indicating that cadherin phosphorylation can be a negative factor for binding to -
catenin.
129




Multiple kinases are involved in β-catenin phosphorylation such as casein kinase I (CK-I) 
and GSK-3β.132, 133 These kinases induce the phosphorylation of β-catenin on Ser33/37 and 
Thr
41
, respectively, leading to its ubiquitination and proteosomal degradation.
132, 133
  Wnt and 
other stimuli lead to the inactivation of GSK-3, thus decreasing -catenin phosphorylation, 
translocation into the nucleus and binding to transcription factors.
115
  In contrary, Ser
552
 






















































phosphorylation level of this serine residue is very low and phospho--catenin Ser552 could be 
detected at the cell periphery of adjacent ECs. Phosphorylation of -catenin at Ser552 by AKT 
leads to its dissociation from cell contacts.
134, 135
 Finally, the inhibition of Ser/Thr 
phosphatases caused hyperphosphorylation of β-catenin on Ser/Thr residues and resulted in 
the loss of cell-cell contacts
131
 implicating the involvement Ser/Thr phosphatases in AJ 
assembly. 
TJs regulate the transport of ions and solutes through the paracellular pathway.
136
 They 
comprise of two families of transmembrane proteins, occludins and claudins as well as their 
cytoplasmic partners, zonula occludens (ZO) proteins, which conne t TJs to actin 
cytoskeleton.
137
 Compared to AJs, mechanisms regulating TJs are far less understood. AJs 
assembly precedes tight junction formation and in some in vivo cases cadherin is required for 
the formation of TJs, as it controls the recruitment of ZO-1 to TJ complexes.
138
 Up-regulation 
of EC-specific claudin-5 isoform is involved in EC barrier enhancement in some, but not all 
models.
139, 140
 Conversely, edemagenic agonists decreased claudin-5 and ZO-1 expression 
accompanied by translocation of ZO-1 from the cytoskeleton to the membrane/nuclear 
fractions.
141, 142
 Recent study implicated the involvement of PKCε/Erk1/2 MAPK axis in 




 This phosphorylation is accompanied by dissociation 
of ZO-1 from occludin resulting in EC barrier dysfunction.
143
 In contrary, cyclic-strain-
induced enhancement of EC barrier function involved increased PKC-dependent ZO-1-
occludin association.
144
 In addition, Tyr phosphorylation of ZO-2 is involved in its 
dissociation from TJs and barrier dysfunction.
145
   
Gap junctions (GJ) form intercellular channels involving in the passages of ions and 
macromolecules between neighboring cells. They also present in ECs and play an important 
role in endothelial functions; however, information regarding the involvement of GJ in EC 






















































EC demonstrated that the expression of TJ protein, connexin 43, is involved in LPS-induced 
permeability increase.
146
 Consistent with these observations, connexin 43 inhibition blocked 
thrombin-induced permeability increase in lung capillaries.
147
 In contrary, other report 
demonstrated that thrombin-induced permeability is accompanied by internalization 
(inhibition) of TJ communications in vascular endothelium.
148
 Further studies are needed to 
define the involvement of TJ in the EC permeability regulation. 
Conclusion. Molecular basis of ALI and ARDS is still poorly understood. Based on the 
existing literature we proposed complex mechanisms involving crosstalk between microtubule 
and microfilaments accompanied by activation/phosphorylation cytoskeletal proteins 
following by re-arrangement of cell junctions. Further studies are needed to define 
cytoskeletal-specific structure/function relationships and enhance our understanding of the 
lung vascular barrier regulation. 
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Figure Legends. 
 
Figure 1. Endothelial activation in ALI. Edemagenic agents like bacterial toxins (LPS) or 
inflammatory mediators (thrombin) disrupt endothelial barrier leading to EC permeability 
increase accompanying by inflammatory response  
 
Figure 2. EC permeability pathways. Edemagenic agonists can increase endothelial 
permeability via caveolae-mediated transcellular route or (and) via increased intercellular 























































Figure 3.  EC cytoskeletal rearrangement in response to edemagenic agonists. Thrombin 
or LPS activates their receptors (PAR-1 and TLR4, respectively) leading to activation of pro-
inflammatory intracellular cascades (intracellular Ca
2+ 
increase, activation of Rho, PKC and 
Src signaling) following by microtubule dissolution, increased MLC phosphorylation (MLCK 
activation, MLCP inhibition) and phosphorylation of regulatory cytoskeletal proteins, CaD 
and HSP-27 (via p38 MAPK activation). These events result in actomyosin contraction, actin 



























































Figure 4.  Hypothetic mechanism of thrombin-induced microtubule-mediated EC 
barrier compromise.  Thrombin activates its receptor (PAR-1) leading to activation of 
trimeric G-proteins (G12/13 and Gq), following by initial activation (phase 1) of Rho and p38 
MAPK signaling and resulting in disruption of microtubule structure via activation of MT-
binding proteins (phosphorylation of tau, CaD and LIMK and dephosphorylation of stathmin).  
At phase 2 MT dissolution leads to further activation of Rho (via release and activation of 
GEF-H1) and p38 MAPK followed by additional phosphorylation of cytoskeletal targets and 
their relocation to actin cytoskeleton resulting in actin rearrangement and permeability 
increase. MT stab: MT stabilization, MT inh: microtubule inhibition.  
 
Figure 5. Schematic representation of major intercellular contacts.          
D
ow
nl
oa
de
d 
by
 [G
eo
rg
ia 
Re
ge
nts
 U
niv
ers
ity
 G
ree
nb
lat
t L
ibr
ary
], 
[A
lex
an
de
r V
eri
n]
 at
 08
:39
 31
 Ja
nu
ary
 20
15
 
